Patents by Inventor Andres Lopez-Albaitero

Andres Lopez-Albaitero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11987642
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: May 21, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Patent number: 11820832
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 21, 2023
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Patent number: 11168150
    Abstract: Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: November 9, 2021
    Assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.
    Inventors: Nai-Kong V. Cheung, Mahiuddin Ahmed, Andres Lopez-Albaitero, Cheng Liu, Su Yan, Jingyi Xiang, Hong Liu
  • Publication number: 20210324079
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Application
    Filed: June 23, 2021
    Publication date: October 21, 2021
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Patent number: 11046768
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 29, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Publication number: 20200199248
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 25, 2020
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Nai-Kong V. CHEUNG, Andres LOPEZ-ALBAITERO, Hong XU
  • Publication number: 20200115470
    Abstract: Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 16, 2020
    Inventors: Nai-Kong V. Cheung, Mahiuddin Ahmed, Andres Lopez-Albaitero, Cheng Liu, Su Yan, Jingyi Xiang, Hong Liu
  • Patent number: 10519248
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: December 31, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Patent number: 10501559
    Abstract: Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: December 10, 2019
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Nai-Kong V. Cheung, Mahiuddin Ahmed, Andres Lopez-Albaitero, Cheng Liu, Su Yan, Jingyi Xiang, Hong Liu
  • Publication number: 20190359732
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Application
    Filed: January 27, 2017
    Publication date: November 28, 2019
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Nai-Kong V. CHEUNG, Andres LOPEZ-ALBAITERO, Hong XU
  • Publication number: 20180273623
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Application
    Filed: January 26, 2018
    Publication date: September 27, 2018
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Publication number: 20180258187
    Abstract: Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.
    Type: Application
    Filed: June 9, 2016
    Publication date: September 13, 2018
    Inventors: Nai-Kong V. Cheung, Mahiuddin Ahmed, Andres Lopez-Albaitero, Cheng Liu, Su Yan, Jingyi Xiang, Hong Liu
  • Publication number: 20170210819
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 27, 2017
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Nai-Kong V. CHEUNG, Andres LOPEZ-ALBAITERO, Hong XU
  • Patent number: 8367069
    Abstract: The invention provides a polypeptide having a sequence of amino acids consisting of IXDFGLAKL (SEQ ID NO: 1), as well as a nucleic acid encoding the polypeptide, vector comprising the nucleic acid, cell comprising the vector, and compositions thereof. The invention also provides a method of inducing a T-cell response in a patient with epithelial cancer, and a method inhibiting epithelial cancer, wherein the methods comprise administering the composition of the invention. The invention further provides a method of stimulating a cell with the inventive polypeptide and a cell so stimulated.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: February 5, 2013
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Robert L. Ferris, Pedro Andrade, Andres Lopez-Albaitero
  • Publication number: 20110171170
    Abstract: The invention provides a polypeptide having a sequence of amino acids consisting of IXDFGLAKL (SEQ ID NO: 1), as well as a nucleic acid encoding the polypeptide, vector comprising the nucleic acid, cell comprising the vector, and compositions thereof. The invention also provides a method of inducing a T-cell response in a patient with epithelial cancer, and a method inhibiting epithelial cancer, wherein the methods comprise administering the composition of the invention. The invention further provides a method of stimulating a cell with the inventive polypeptide and a cell so stimulated.
    Type: Application
    Filed: December 2, 2010
    Publication date: July 14, 2011
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Robert L. Ferris, Pedro Andrade, Andres Lopez-Albaitero